Therapies for polycystic kidney disease

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review All polycystic diseases of the kidney exhibit tubular or saccular cysts. The cysts can either be open to the tubule or isolated sacs that have lost their connections. Polycystic kidney diseases derived from different genetic mutations share basic mechanisms of cytogenesis, formation, and progressive enlargement, involving a cellular organelle called the primary cilium. Given the mechanistic commonalities, this review will focus on the therapeutic approaches currently available or under development that likely apply to all inherited renal cystic diseases. Recent findings Recent advances in clinical trials and preclinical experiments have illuminated common signaling pathway involvement. Summary Avoidance of nephrotoxic drugs or radio-contrast and maintaining normal BMI are routine preventive measures. Limiting the intake of calories, salt, and protein, together with increased intake of fruits, vegetables, and water are dietary treatments that should be started early in the course of the disease. Potential pharmacological treatments targeting cyst initiation and progression are on the horizon.

Original languageEnglish (US)
Pages (from-to)227-232
Number of pages6
JournalCurrent Opinion in Pediatrics
Volume27
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Polycystic Kidney Diseases
Cysts
Cystic Kidney Diseases
Cilia
Water Purification
Radio
Vegetables
Organelles
Fruit
Therapeutics
Salts
Clinical Trials
Pharmacology
Mutation
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Therapies for polycystic kidney disease. / Bissler, John.

In: Current Opinion in Pediatrics, Vol. 27, No. 2, 01.01.2015, p. 227-232.

Research output: Contribution to journalReview article

@article{5ce5080a380849dbbe0e4d797a1d0d8c,
title = "Therapies for polycystic kidney disease",
abstract = "Purpose of review All polycystic diseases of the kidney exhibit tubular or saccular cysts. The cysts can either be open to the tubule or isolated sacs that have lost their connections. Polycystic kidney diseases derived from different genetic mutations share basic mechanisms of cytogenesis, formation, and progressive enlargement, involving a cellular organelle called the primary cilium. Given the mechanistic commonalities, this review will focus on the therapeutic approaches currently available or under development that likely apply to all inherited renal cystic diseases. Recent findings Recent advances in clinical trials and preclinical experiments have illuminated common signaling pathway involvement. Summary Avoidance of nephrotoxic drugs or radio-contrast and maintaining normal BMI are routine preventive measures. Limiting the intake of calories, salt, and protein, together with increased intake of fruits, vegetables, and water are dietary treatments that should be started early in the course of the disease. Potential pharmacological treatments targeting cyst initiation and progression are on the horizon.",
author = "John Bissler",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MOP.0000000000000202",
language = "English (US)",
volume = "27",
pages = "227--232",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Therapies for polycystic kidney disease

AU - Bissler, John

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose of review All polycystic diseases of the kidney exhibit tubular or saccular cysts. The cysts can either be open to the tubule or isolated sacs that have lost their connections. Polycystic kidney diseases derived from different genetic mutations share basic mechanisms of cytogenesis, formation, and progressive enlargement, involving a cellular organelle called the primary cilium. Given the mechanistic commonalities, this review will focus on the therapeutic approaches currently available or under development that likely apply to all inherited renal cystic diseases. Recent findings Recent advances in clinical trials and preclinical experiments have illuminated common signaling pathway involvement. Summary Avoidance of nephrotoxic drugs or radio-contrast and maintaining normal BMI are routine preventive measures. Limiting the intake of calories, salt, and protein, together with increased intake of fruits, vegetables, and water are dietary treatments that should be started early in the course of the disease. Potential pharmacological treatments targeting cyst initiation and progression are on the horizon.

AB - Purpose of review All polycystic diseases of the kidney exhibit tubular or saccular cysts. The cysts can either be open to the tubule or isolated sacs that have lost their connections. Polycystic kidney diseases derived from different genetic mutations share basic mechanisms of cytogenesis, formation, and progressive enlargement, involving a cellular organelle called the primary cilium. Given the mechanistic commonalities, this review will focus on the therapeutic approaches currently available or under development that likely apply to all inherited renal cystic diseases. Recent findings Recent advances in clinical trials and preclinical experiments have illuminated common signaling pathway involvement. Summary Avoidance of nephrotoxic drugs or radio-contrast and maintaining normal BMI are routine preventive measures. Limiting the intake of calories, salt, and protein, together with increased intake of fruits, vegetables, and water are dietary treatments that should be started early in the course of the disease. Potential pharmacological treatments targeting cyst initiation and progression are on the horizon.

UR - http://www.scopus.com/inward/record.url?scp=84962033228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962033228&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000202

DO - 10.1097/MOP.0000000000000202

M3 - Review article

VL - 27

SP - 227

EP - 232

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 2

ER -